Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
Journal Article
|Research
2020-05-02 • Journal of Viral Hepatitis
2020-05-02 • Journal of Viral Hepatitis
Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF+DCV) facilitate simplified models of care for hepatitis C virus (HCV). ...
Journal Article
|Research
2020-11-04 • Journal of Viral Hepatitis
2020-11-04 • Journal of Viral Hepatitis
Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...
Journal Article
|Commentary
2013-08-05 • Journal of Viral Hepatitis
2013-08-05 • Journal of Viral Hepatitis
Journal Article
|Research
2022-03-12 • Journal of Viral Hepatitis
2022-03-12 • Journal of Viral Hepatitis
Achieving global elimination of hepatitis C virus requires a substantial scale-up of testing. Point-of-care HCV viral load assays are available as an alternative to laboratory-based assa...
Journal Article
|Research
2018-07-26 • Journal of Viral Hepatitis
2018-07-26 • Journal of Viral Hepatitis
Hepatitis B virus (HBV) infection is hyperendemic in Cameroon, and health care workers (HCWs) are at high-risk of infection. We aimed to assess prevalence, risk factors and vaccine cover...
Journal Article
|Research
2018-12-03 • Journal of Viral Hepatitis
2018-12-03 • Journal of Viral Hepatitis
GeneXpert® (Cepheid) is the only WHO prequalified platform for hepatitis C virus (HCV) nucleic acid amplification testing that is suitable for point-of-care use in resource-limited conte...